Gastroenterology / Hepatology General Medicine Strong — EASL/AASLD Guideline Recommended
FIB-4 Index
Non-invasive assessment of liver fibrosis in chronic liver disease (NAFLD, hepatitis B/C).
References
- Sterling RK et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006.
- European Association for the Study of the Liver (EASL). Clinical Practice Guidelines: Management of NAFLD. J Hepatol. 2016.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Spironolactone (Ascites / Cirrhosis) · Aldosterone Antagonist / Potassium-Sparing Diuretic
- Furosemide (Ascites / Cirrhosis) · Loop Diuretic
- Entecavir · Antiviral — Hepatitis B (Nucleoside Analogue)
- Tenofovir (TDF/TAF) · Antiviral — Hepatitis B (Nucleotide Analogue)
- Glecaprevir / Pibrentasvir · Antiviral — Hepatitis C (Pan-Genotypic DAA)
- Sofosbuvir / Velpatasvir · Antiviral — Hepatitis C (Pan-Genotypic DAA)
Pathways
- Sepsis Screening and Sepsis Six · UK Sepsis Trust; NICE NG51; Surviving Sepsis Campaign 2021
- Unintentional Weight Loss Workup · NICE NG12; BSG
- Chronic Fatigue Workup · NICE NG206; BMJ Best Practice
- Lymphadenopathy Workup · NICE NG12; BMJ Best Practice
- Pre-op Medical Clearance · NICE NG45; ESC 2022
- Secondary Hypertension Workup · NICE NG136; ESH 2023
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.